Silexion expands SIL204 development with dual-route plan; preclinical data support; H1 2026 human trials targeted

Silexion Therapeutics Corp

Expanded development plan for SIL204 combines intratumoral and systemic administration for KRAS-driven pancreatic cancer.
Preclinical orthotopic model data show systemic SIL204 significantly inhibits tumor growth and reduces metastases.
Toxicology and pharmacodynamic studies planned through 2025; regulatory submissions to Israel Ministry of Health in H2 2025 and EU in H1 2026.
Goal to initiate SIL204 human trials in H1 2026 for advanced localized KRAS-driven pancreatic cancer.
First-generation product siG12DLoder previously showed overall survival benefit in Phase 2, supporting the expanded approach.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.